FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912452769> ?p ?o ?g. }

• W2912452769 abstract "Overall survival is the true endpoint for most randomized controlled trials (RCTs) of malignant tumors, whereas progression-free survival (PFS) is considered the most reliable surrogate endpoint for overall survival (OS). The present study aimed to evaluate the correlation between surrogate endpoints and OS in randomized trials of first-line chemotherapy with doxorubicin (DOX), the standard treatment for advanced and metastatic soft tissue sarcomas (ASTS), using a meta-analytic approach. In a systematic review, we identified RCTs of first-line chemotherapy for ASTS that compared single-agent doxorubicin (DOX) with other chemotherapy regimens, and were published in English during January 1974–December 2017. A meta-analysis was performed to evaluate the efficacy of first-line treatments for ASTS. Surrogacy of the intermediate endpoints for OS was investigated using weighted linear regression analysis. Correlation strength was examined using the coefficient of determination (R2). Twenty-seven randomized trials, comprising 6156 patients (3371 patients in the experimental arm and 2785 patients in the DOX arm) were identified. The hazard ratios for OS and PFS showed that the efficacy of treatment for ASTS was not significantly different between standard DOX and experimental treatments. The median OS was significantly prolonged in RCTs published after 2012 when pazopanib was approved for treating ASTS. The median PFS, however, did not differ significantly. The correlation between PFS and OS was moderate (R2 = 0.557), but better than that between OS and 3-month PFS, 6-month PFS, and response rate (R2 = 0.200, 0.073, and 0.278, respectively). The correlation between PFS and OS tended to be more favorable in RCTs published after 2012 (R2 = 0.586 and 0.459, respectively). The trial-level correlation between PFS and OS was only modest; it tended to be better in RCTs published after 2012. While the effective lines of chemotherapy and the introduction of new drugs prolonged OS but not PFS, PFS is a better surrogate than other intermediate endpoints in the first-line ASTS trials even in the post-pazopanib era. Although this does not negate the need for more reliable surrogate endpoints for OS." @default.
• W2912452769 created "2019-02-21" @default.
• W2912452769 creator A5021128845 @default.
• W2912452769 creator A5022274058 @default.
• W2912452769 creator A5031839194 @default.
• W2912452769 creator A5075003242 @default.
• W2912452769 creator A5076919182 @default.
• W2912452769 date "2019-01-11" @default.
• W2912452769 modified "2023-09-23" @default.
• W2912452769 title "Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation" @default.
• W2912452769 cites W1496021054 @default.
• W2912452769 cites W1589920570 @default.
• W2912452769 cites W1882650898 @default.
• W2912452769 cites W1892579032 @default.
• W2912452769 cites W1906474388 @default.
• W2912452769 cites W1943427806 @default.
• W2912452769 cites W1955072209 @default.
• W2912452769 cites W2010948762 @default.
• W2912452769 cites W2013000677 @default.
• W2912452769 cites W2021484735 @default.
• W2912452769 cites W2038448746 @default.
• W2912452769 cites W2052813039 @default.
• W2912452769 cites W2057195209 @default.
• W2912452769 cites W2069693587 @default.
• W2912452769 cites W2082065626 @default.
• W2912452769 cites W2083438316 @default.
• W2912452769 cites W2085480583 @default.
• W2912452769 cites W2092722132 @default.
• W2912452769 cites W2095645261 @default.
• W2912452769 cites W2100243692 @default.
• W2912452769 cites W2101776780 @default.
• W2912452769 cites W2102347194 @default.
• W2912452769 cites W2126133903 @default.
• W2912452769 cites W2136344041 @default.
• W2912452769 cites W2140075859 @default.
• W2912452769 cites W2143427907 @default.
• W2912452769 cites W2156098321 @default.
• W2912452769 cites W2160752563 @default.
• W2912452769 cites W2161378536 @default.
• W2912452769 cites W2165252656 @default.
• W2912452769 cites W2167422856 @default.
• W2912452769 cites W2259955047 @default.
• W2912452769 cites W2293085462 @default.
• W2912452769 cites W2293716668 @default.
• W2912452769 cites W2397619801 @default.
• W2912452769 cites W2412779796 @default.
• W2912452769 cites W2413552560 @default.
• W2912452769 cites W2432945817 @default.
• W2912452769 cites W2464988286 @default.
• W2912452769 cites W2513128159 @default.
• W2912452769 cites W2653632515 @default.
• W2912452769 cites W2752560124 @default.
• W2912452769 cites W2989800034 @default.
• W2912452769 cites W2991792334 @default.
• W2912452769 doi "https://doi.org/10.1186/s12885-019-5268-2" @default.
• W2912452769 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6330427" @default.
• W2912452769 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30634944" @default.
• W2912452769 hasPublicationYear "2019" @default.
• W2912452769 type Work @default.
• W2912452769 sameAs 2912452769 @default.
• W2912452769 citedByCount "11" @default.
• W2912452769 countsByYear W29124527692020 @default.
• W2912452769 countsByYear W29124527692021 @default.
• W2912452769 countsByYear W29124527692022 @default.
• W2912452769 crossrefType "journal-article" @default.
• W2912452769 hasAuthorship W2912452769A5021128845 @default.
• W2912452769 hasAuthorship W2912452769A5022274058 @default.
• W2912452769 hasAuthorship W2912452769A5031839194 @default.
• W2912452769 hasAuthorship W2912452769A5075003242 @default.
• W2912452769 hasAuthorship W2912452769A5076919182 @default.
• W2912452769 hasBestOaLocation W29124527691 @default.
• W2912452769 hasConcept C121608353 @default.
• W2912452769 hasConcept C126322002 @default.
• W2912452769 hasConcept C141341695 @default.
• W2912452769 hasConcept C142724271 @default.
• W2912452769 hasConcept C143998085 @default.
• W2912452769 hasConcept C168563851 @default.
• W2912452769 hasConcept C203092338 @default.
• W2912452769 hasConcept C207103383 @default.
• W2912452769 hasConcept C2776694085 @default.
• W2912452769 hasConcept C2778256501 @default.
• W2912452769 hasConcept C2778439243 @default.
• W2912452769 hasConcept C2778629024 @default.
• W2912452769 hasConcept C2779490328 @default.
• W2912452769 hasConcept C2780739268 @default.
• W2912452769 hasConcept C2781303535 @default.
• W2912452769 hasConcept C44249647 @default.
• W2912452769 hasConcept C71924100 @default.
• W2912452769 hasConceptScore W2912452769C121608353 @default.
• W2912452769 hasConceptScore W2912452769C126322002 @default.
• W2912452769 hasConceptScore W2912452769C141341695 @default.
• W2912452769 hasConceptScore W2912452769C142724271 @default.
• W2912452769 hasConceptScore W2912452769C143998085 @default.
• W2912452769 hasConceptScore W2912452769C168563851 @default.
• W2912452769 hasConceptScore W2912452769C203092338 @default.
• W2912452769 hasConceptScore W2912452769C207103383 @default.
• W2912452769 hasConceptScore W2912452769C2776694085 @default.
• W2912452769 hasConceptScore W2912452769C2778256501 @default.
• W2912452769 hasConceptScore W2912452769C2778439243 @default.
• W2912452769 hasConceptScore W2912452769C2778629024 @default.

• next